Corrigendum

In the Clinical Trial Report by Claudio Borghi, Stefano Bacchelli and Daniela Degli Esposti, ‘Long-term clinical experience with zofenopril’, published in the August 2012 issue of Expert Review of Cardiovascular Therapy (Expert Rev. Cardiovasc. Ther. 10[8], 973–982 [2012]), the following sentence appeared as:

“The SMILE trial was designed to test the hypothesis that the administration of zofenopril (15–60 mg twice daily or placebo) administered within 24 h of the onset of symptoms for 6 weeks would improve the clinical outcome of 1556 high-risk patients with acute anterior MI not receiving thrombolysis [21,22].”

The sentence should have read:

“The SMILE trial was designed to test the hypothesis that the administration of zofenopril (15–60 mg/day or placebo) administered within 24 h of the onset of symptoms for 6 weeks would improve the clinical outcome of 1556 high-risk patients with acute anterior MI not receiving thrombolysis [21,22].”

In addition, the following figures appeared as:

Figure 3. One-year mortality rate in the SMILE study.

Adapted with permission from [22].

Figure 4. One-year survival in patients with acute myocardial infarction and history of hypertension treated with zofenopril or placebo.

RR: Risk reduction.

Adapted with permission from [26].

Figure 5. Combined occurrence of death and severe congestive heart failure (primary end point) during the 6 weeks of double-blind treatment in the diabetic and nondiabetic population of the SMILE study.

RR: Risk reduction.

Data taken from [28].

Figure 8. Overall benefit of zofenopril treatment in the different studies of the SMILE project.

RR: Risk reduction.

The figures should have appeared as:

Figure 3. One-year mortality rate in the SMILE study.

Adapted with permission from [22].

Figure 4. One-year survival in patients with acute myocardial infarction and history of hypertension treated with zofenopril or placebo.

RR: Risk reduction.

Adapted with permission from [26].

Figure 5. Combined occurrence of death and severe congestive heart failure (primary end point) during the 6 weeks of double-blind treatment in the diabetic and nondiabetic population of the SMILE study.

RR: Risk reduction.

Data taken from [28].

Figure 8. Overall benefit of zofenopril treatment in the different studies of the SMILE project.

RR: Risk reduction.

The authors and editors of Expert Review of Cardiovascular Therapy would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.